Annual EBIT
$26.28 M
+$44.50 M+244.27%
December 31, 2024
Summary
- As of March 8, 2025, RIGL annual earnings before interest & taxes is $26.28 million, with the most recent change of +$44.50 million (+244.27%) on December 31, 2024.
- During the last 3 years, RIGL annual EBIT has risen by +$38.73 million (+311.13%).
- RIGL annual EBIT is now -30.80% below its all-time high of $37.98 million, reached on December 31, 2010.
Performance
RIGL EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
$17.18 M
+$2.70 M+18.62%
December 31, 2024
Summary
- As of March 8, 2025, RIGL quarterly earnings before interest & taxes is $17.18 million, with the most recent change of +$2.70 million (+18.62%) on December 31, 2024.
- Over the past year, RIGL quarterly EBIT has increased by +$2.70 million (+18.62%).
- RIGL quarterly EBIT is now -65.95% below its all-time high of $50.45 million, reached on September 30, 2010.
Performance
RIGL Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
$26.28 M
+$14.53 M+123.67%
December 31, 2024
Summary
- As of March 8, 2025, RIGL TTM earnings before interest & taxes is $26.28 million, with the most recent change of +$14.53 million (+123.67%) on December 31, 2024.
- Over the past year, RIGL TTM EBIT has increased by +$14.53 million (+123.67%).
- RIGL TTM EBIT is now -33.20% below its all-time high of $39.35 million, reached on March 31, 2011.
Performance
RIGL TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RIGL EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +244.3% | +18.6% | +123.7% |
| 3 y3 years | +311.1% | +18.6% | +123.7% |
| 5 y5 years | +139.5% | +18.6% | +123.7% |
RIGL EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +147.9% | at high | +165.5% | at high | +132.7% |
| 5 y | 5-year | at high | +139.5% | -58.9% | +165.5% | at high | +132.7% |
| alltime | all time | -30.8% | +119.9% | -66.0% | +144.4% | -33.2% | +119.7% |
Rigel Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $26.28 M(-244.3%) | $17.18 M(+18.6%) | $26.28 M(+123.7%) |
| Sep 2024 | - | $14.48 M(+1349.5%) | $11.75 M(-280.1%) |
| Jun 2024 | - | $999.00 K(-115.7%) | -$6.52 M(-46.8%) |
| Mar 2024 | - | -$6.37 M(-341.0%) | -$12.26 M(-32.7%) |
| Dec 2023 | -$18.22 M(-66.8%) | $2.64 M(-169.7%) | -$18.22 M(-0.7%) |
| Sep 2023 | - | -$3.79 M(-19.9%) | -$18.36 M(-44.0%) |
| Jun 2023 | - | -$4.74 M(-61.6%) | -$32.77 M(-20.0%) |
| Mar 2023 | - | -$12.33 M(-591.7%) | -$40.96 M(-25.3%) |
| Dec 2022 | -$54.87 M(+340.7%) | $2.51 M(-113.8%) | -$54.87 M(-30.4%) |
| Sep 2022 | - | -$18.21 M(+40.9%) | -$78.78 M(-1.9%) |
| Jun 2022 | - | -$12.92 M(-50.8%) | -$80.34 M(-0.1%) |
| Mar 2022 | - | -$26.24 M(+22.6%) | -$80.44 M(+546.2%) |
| Dec 2021 | -$12.45 M(-56.2%) | -$21.40 M(+8.2%) | -$12.45 M(+26.3%) |
| Sep 2021 | - | -$19.77 M(+51.7%) | -$9.86 M(+157.4%) |
| Jun 2021 | - | -$13.03 M(-131.2%) | -$3.83 M(-52.3%) |
| Mar 2021 | - | $41.76 M(-322.0%) | -$8.02 M(-71.8%) |
| Dec 2020 | -$28.39 M(-57.3%) | -$18.81 M(+36.8%) | -$28.39 M(+7.3%) |
| Sep 2020 | - | -$13.74 M(-20.2%) | -$26.46 M(+9.4%) |
| Jun 2020 | - | -$17.22 M(-180.5%) | -$24.19 M(-12.3%) |
| Mar 2020 | - | $21.39 M(-226.7%) | -$27.58 M(-58.6%) |
| Dec 2019 | -$66.56 M(-5.6%) | -$16.87 M(+47.0%) | -$66.56 M(+43.3%) |
| Sep 2019 | - | -$11.48 M(-44.3%) | -$46.46 M(-20.9%) |
| Jun 2019 | - | -$20.61 M(+17.1%) | -$58.74 M(-8.6%) |
| Mar 2019 | - | -$17.60 M(-645.2%) | -$64.25 M(-10.0%) |
| Dec 2018 | -$70.48 M(-9.6%) | $3.23 M(-113.6%) | -$71.38 M(-28.0%) |
| Sep 2018 | - | -$23.77 M(-9.0%) | -$99.20 M(+6.3%) |
| Jun 2018 | - | -$26.11 M(+5.6%) | -$93.29 M(+7.8%) |
| Mar 2018 | - | -$24.73 M(+0.6%) | -$86.52 M(+10.9%) |
| Dec 2017 | -$77.99 M(+21.9%) | -$24.59 M(+37.7%) | -$77.99 M(+12.7%) |
| Sep 2017 | - | -$17.86 M(-7.7%) | -$69.19 M(+1.3%) |
| Jun 2017 | - | -$19.34 M(+19.4%) | -$68.30 M(+9.1%) |
| Mar 2017 | - | -$16.20 M(+2.6%) | -$62.61 M(-2.1%) |
| Dec 2016 | -$63.97 M(+23.6%) | -$15.79 M(-7.0%) | -$63.97 M(+5.0%) |
| Sep 2016 | - | -$16.97 M(+24.3%) | -$60.93 M(+20.1%) |
| Jun 2016 | - | -$13.65 M(-22.3%) | -$50.74 M(-0.6%) |
| Mar 2016 | - | -$17.57 M(+37.8%) | -$51.07 M(-1.3%) |
| Dec 2015 | -$51.74 M(-43.3%) | -$12.75 M(+88.0%) | -$51.74 M(-15.7%) |
| Sep 2015 | - | -$6.78 M(-51.5%) | -$61.36 M(-18.9%) |
| Jun 2015 | - | -$13.97 M(-23.4%) | -$75.62 M(-13.2%) |
| Mar 2015 | - | -$18.24 M(-18.5%) | -$87.11 M(-4.5%) |
| Dec 2014 | -$91.25 M(+3.9%) | -$22.37 M(+6.3%) | -$91.25 M(+6.3%) |
| Sep 2014 | - | -$21.04 M(-17.3%) | -$85.83 M(-1.4%) |
| Jun 2014 | - | -$25.46 M(+13.7%) | -$87.04 M(+3.0%) |
| Mar 2014 | - | -$22.39 M(+32.1%) | -$84.47 M(-3.8%) |
| Dec 2013 | -$87.79 M(-11.7%) | -$16.94 M(-23.9%) | -$87.79 M(-9.0%) |
| Sep 2013 | - | -$22.25 M(-2.8%) | -$96.46 M(-3.3%) |
| Jun 2013 | - | -$22.89 M(-11.0%) | -$99.78 M(-2.0%) |
| Mar 2013 | - | -$25.71 M(+0.4%) | -$101.78 M(+2.4%) |
| Dec 2012 | -$99.38 M | -$25.62 M(+0.2%) | -$99.38 M(+0.1%) |
| Sep 2012 | - | -$25.57 M(+2.8%) | -$99.25 M(+8.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2012 | - | -$24.88 M(+6.7%) | -$91.72 M(+3.8%) |
| Mar 2012 | - | -$23.31 M(-8.6%) | -$88.40 M(+2.9%) |
| Dec 2011 | -$85.95 M(-326.3%) | -$25.49 M(+41.3%) | -$85.95 M(+10.6%) |
| Sep 2011 | - | -$18.04 M(-16.3%) | -$77.68 M(+745.5%) |
| Jun 2011 | - | -$21.56 M(+3.3%) | -$9.19 M(-123.3%) |
| Mar 2011 | - | -$20.86 M(+21.2%) | $39.35 M(+3.9%) |
| Dec 2010 | $37.98 M(-134.1%) | -$17.22 M(-134.1%) | $37.86 M(+26.1%) |
| Sep 2010 | - | $50.45 M(+87.0%) | $30.02 M(-163.8%) |
| Jun 2010 | - | $26.98 M(-220.7%) | -$47.03 M(-54.7%) |
| Mar 2010 | - | -$22.35 M(-10.8%) | -$103.85 M(-6.8%) |
| Dec 2009 | -$111.44 M(-15.8%) | -$25.06 M(-5.8%) | -$111.44 M(-3.9%) |
| Sep 2009 | - | -$26.61 M(-10.8%) | -$115.95 M(-9.4%) |
| Jun 2009 | - | -$29.84 M(-0.3%) | -$128.03 M(-4.1%) |
| Mar 2009 | - | -$29.93 M(+1.2%) | -$133.47 M(+0.9%) |
| Dec 2008 | -$132.28 M(+66.3%) | -$29.57 M(-23.6%) | -$132.28 M(+7.6%) |
| Sep 2008 | - | -$38.68 M(+9.7%) | -$122.96 M(+17.4%) |
| Jun 2008 | - | -$35.28 M(+22.7%) | -$104.70 M(+16.3%) |
| Mar 2008 | - | -$28.75 M(+41.9%) | -$90.03 M(+13.2%) |
| Dec 2007 | -$79.53 M(+84.7%) | -$20.26 M(-0.8%) | -$79.53 M(+4.4%) |
| Sep 2007 | - | -$20.43 M(-0.9%) | -$76.16 M(+11.2%) |
| Jun 2007 | - | -$20.61 M(+13.0%) | -$68.47 M(+33.0%) |
| Mar 2007 | - | -$18.24 M(+8.0%) | -$51.47 M(+19.6%) |
| Dec 2006 | -$43.05 M(-10.2%) | -$16.89 M(+32.7%) | -$43.05 M(+18.8%) |
| Sep 2006 | - | -$12.73 M(+252.6%) | -$36.24 M(-2.8%) |
| Jun 2006 | - | -$3.61 M(-63.2%) | -$37.29 M(-19.5%) |
| Mar 2006 | - | -$9.82 M(-2.7%) | -$46.31 M(-3.4%) |
| Dec 2005 | -$47.92 M(-15.7%) | -$10.09 M(-26.8%) | -$47.92 M(-9.1%) |
| Sep 2005 | - | -$13.78 M(+9.1%) | -$52.74 M(-4.6%) |
| Jun 2005 | - | -$12.63 M(+10.5%) | -$55.28 M(+0.2%) |
| Mar 2005 | - | -$11.43 M(-23.3%) | -$55.18 M(-3.0%) |
| Dec 2004 | -$56.87 M(+39.3%) | -$14.90 M(-8.7%) | -$56.87 M(+5.6%) |
| Sep 2004 | - | -$16.32 M(+30.3%) | -$53.84 M(+10.9%) |
| Jun 2004 | - | -$12.53 M(-4.5%) | -$48.57 M(+4.7%) |
| Mar 2004 | - | -$13.12 M(+10.5%) | -$46.40 M(+13.7%) |
| Dec 2003 | -$40.83 M(+10.3%) | -$11.87 M(+7.5%) | -$40.83 M(+10.5%) |
| Sep 2003 | - | -$11.05 M(+6.6%) | -$36.94 M(+2.6%) |
| Jun 2003 | - | -$10.36 M(+37.3%) | -$36.00 M(-0.4%) |
| Mar 2003 | - | -$7.55 M(-5.5%) | -$36.13 M(-2.4%) |
| Dec 2002 | -$37.02 M(+48.3%) | -$7.99 M(-20.9%) | -$37.02 M(+5.1%) |
| Sep 2002 | - | -$10.10 M(-3.7%) | -$35.23 M(+11.7%) |
| Jun 2002 | - | -$10.49 M(+24.3%) | -$31.55 M(+10.1%) |
| Mar 2002 | - | -$8.44 M(+36.0%) | -$28.65 M(+14.8%) |
| Dec 2001 | -$24.96 M(-2.1%) | -$6.20 M(-3.3%) | -$24.96 M(-54.0%) |
| Sep 2001 | - | -$6.42 M(-15.5%) | -$54.27 M(+21.9%) |
| Jun 2001 | - | -$7.60 M(+60.1%) | -$44.52 M(+32.6%) |
| Mar 2001 | - | -$4.74 M(-86.6%) | -$33.59 M(+31.7%) |
| Dec 2000 | -$25.50 M(+111.1%) | -$35.51 M(-1164.5%) | -$25.50 M(-354.8%) |
| Sep 2000 | - | $3.34 M(0.0%) | $10.01 M(+50.0%) |
| Jun 2000 | - | $3.34 M(0.0%) | $6.67 M(+100.0%) |
| Mar 2000 | - | $3.34 M | $3.34 M |
| Dec 1999 | -$12.08 M | - | - |
FAQ
- What is Rigel Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals annual EBIT year-on-year change?
- What is Rigel Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals quarterly EBIT year-on-year change?
- What is Rigel Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals TTM EBIT year-on-year change?
What is Rigel Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of RIGL is $26.28 M
What is the all time high annual EBIT for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high annual earnings before interest & taxes is $37.98 M
What is Rigel Pharmaceuticals annual EBIT year-on-year change?
Over the past year, RIGL annual earnings before interest & taxes has changed by +$44.50 M (+244.27%)
What is Rigel Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of RIGL is $17.18 M
What is the all time high quarterly EBIT for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high quarterly earnings before interest & taxes is $50.45 M
What is Rigel Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, RIGL quarterly earnings before interest & taxes has changed by +$2.70 M (+18.62%)
What is Rigel Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of RIGL is $26.28 M
What is the all time high TTM EBIT for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high TTM earnings before interest & taxes is $39.35 M
What is Rigel Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, RIGL TTM earnings before interest & taxes has changed by +$14.53 M (+123.67%)